Literature DB >> 32057141

Heroin-induced respiratory depression and the influence of dose variation: within-subject between-session changes following dose reduction.

Basak Tas1, Caroline J Jolley2, Nicola J Kalk1,3, Rob van der Waal3, James Bell1, John Strang1,3.   

Abstract

BACKGROUND AND AIMS: Globally, more than 100 000 people die annually from opioid overdose. Opportunities to study physiological events in at-risk individuals are limited. This study examined variation of opioid dose and impact on respiratory depression in a chronic injecting heroin user at separate time-points during his long-term diamorphine maintenance treatment.
DESIGN: A single-subject study over 5 years during which participant underwent experimental studies on diamorphine-induced respiratory depression, at changing maintenance doses.
SETTING: A clinical research facility. Participant Male subject on long-term injectable diamorphine (pharmaceutical heroin) maintenance treatment for heroin addiction. MEASUREMENTS: Physiological measures of oxygen saturation (SpO2 ), end-tidal carbon dioxide (ETCO2 ) and respiratory rate (RR) were used to indicate severity of respiratory depression.
FINDINGS: (1) After diamorphine injection, respiratory regulation became abnormal, with prolonged apnoea exceeding 20 sec (maximum 56 sec), elevated ETCO2 (maximum 6.9%) and hypoxaemia (minimum SpO2 80%). (2) Abnormalities were greater with highest diamorphine dose: average SpO2 was 89.3% after 100 mg diamorphine versus 93.6% and 92.8% for the two 30-mg doses. (3) However, long apnoeic pauses and high levels of ETCO2 % were also present after lower doses.
CONCLUSIONS: With marked inter-session variability, these findings corroborate observations of inconsistent relationships between opioid dose and overdose risk.
© 2020 Society for the Study of Addiction.

Entities:  

Keywords:  Depression; HAT; heroin; opioid; overdose; respiratory

Mesh:

Substances:

Year:  2020        PMID: 32057141     DOI: 10.1111/add.15014

Source DB:  PubMed          Journal:  Addiction        ISSN: 0965-2140            Impact factor:   6.526


  5 in total

1.  Changes in the development of opioid tolerance on re-exposure among people who use heroin: A qualitative study.

Authors:  Joanna May Kesten; Ed Holder; Rachel Ayres; Pete Ellis; Steve Taylor; Matthew Hickman; Graeme Henderson
Journal:  PLoS One       Date:  2022-06-23       Impact factor: 3.752

2.  FORWARDS-1: an adaptive, single-blind, placebo-controlled ascending dose study of acute baclofen on safety parameters in opioid dependence during methadone-maintenance treatment-a pharmacokinetic-pharmacodynamic study.

Authors:  L M Paterson; D Barker; S Cro; P Mozgunov; R Phillips; C Smith; L Nahar; S Paterson; A R Lingford-Hughes
Journal:  Trials       Date:  2022-10-18       Impact factor: 2.728

3.  6-Monoacetylmorphine-antibody distribution in tissues from heroin-related death cases: An experimental study to investigate the distributive response.

Authors:  Aniello Maiese; Raffaele La Russa; Maria Chiara David; Santina Cantatore; Alice Chiara Manetti; Alessandra De Matteis; Costantino Ciallella; Paola Frati; Vittorio Fineschi
Journal:  J Cell Mol Med       Date:  2022-08-02       Impact factor: 5.295

4.  Evidence from naturalistic studies can be strengthened by triangulation.

Authors:  Tom P Freeman; Jenny Scott; Gemma M J Taylor
Journal:  Addiction       Date:  2022-04-17       Impact factor: 7.256

5.  Could COVID expand the future of addiction research? Long-term implications in the pandemic era.

Authors:  Amir Englund; Stephen Sharman; Basak Tas; John Strang
Journal:  Addiction       Date:  2022-01-25       Impact factor: 7.256

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.